{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397758,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Arcutis"},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01393-3","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T03:47:23Z","timestamp":1744688843000},"page":"1555-1567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of Challenging Psoriasis Clinical Scenarios"],"prefix":"10.1007","volume":"15","author":[{"given":"Linda","family":"Stein Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad P.","family":"Glick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najat M.","family":"Watch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodie","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"8","key":"1393_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2007.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1393_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1393_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13555-021-00521-z","volume":"11","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther (Heidelb). 2021;11(3):769\u201397. https:\/\/doi.org\/10.1007\/s13555-021-00521-z.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1393_CR4","unstructured":"Arcutis Biotherapeutics. Zoryve cream. Prescribing information. 2024. https:\/\/www.arcutis.com\/wp-content\/uploads\/USPI-roflumilast-cream.pdf. Accessed 19 Nov 2024."},{"key":"1393_CR5","unstructured":"Arcutis Biotherapeutics. Zoryve foam. Prescribing information. 2023. https:\/\/www.arcutis.com\/wp-content\/uploads\/zoryve-foam-pi-hcp.pdf. Accessed 19 Nov 2024."},{"key":"1393_CR6","unstructured":"Dermavant Sciences Inc. Vtama cream. Prescribing information. 2024. https:\/\/vtamahcp.com\/PI\/. Accessed 24 Jan 2025."},{"key":"1393_CR7","doi-asserted-by":"publisher","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study [published correction appears in Arthritis Rheum. 2010 Apr;62(4):574].\u00a0Arthritis Rheum. 2009;61(2):233\u2013239. https:\/\/doi.org\/10.1002\/art.24172.","DOI":"10.1002\/art.24172"},{"issue":"1","key":"1393_CR8","doi-asserted-by":"publisher","first-page":"s18","DOI":"10.25251\/skin.5.supp.18","volume":"5","author":"K Papp","year":"2021","unstructured":"Papp K, Lebwohl M, Gottlieb A, et al. Bimekizumab for the treatment of moderate to severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase 3 trial. SKIN J Cutan Med. 2021;5(1):s18. https:\/\/doi.org\/10.25251\/skin.5.supp.18.","journal-title":"SKIN J Cutan Med."},{"issue":"1","key":"1393_CR9","doi-asserted-by":"publisher","first-page":"s304","DOI":"10.25251\/skin.8.supp.304","volume":"8","author":"JF Merola","year":"2024","unstructured":"Merola JF, Conrad C, Hampton P, et al. Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: pooled results from five phase 3\/3b trials. SKIN J Cutan Med. 2024;8(1):s304. https:\/\/doi.org\/10.25251\/skin.8.supp.304.","journal-title":"SKIN J Cutan Med"},{"issue":"4","key":"1393_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","volume":"28","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatol Treat. 2017;28(4):282\u20137. https:\/\/doi.org\/10.1080\/09546634.2016.1249820.","journal-title":"J Dermatol Treat."},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"1185523","DOI":"10.3389\/fmed.2023.1185523","volume":"10","author":"S Piaserico","year":"2023","unstructured":"Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational psoriasis study of health outcomes (PSoHO). Front Med (Lausanne). 2023;10:1185523. https:\/\/doi.org\/10.3389\/fmed.2023.1185523.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1393_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40257-019-00480-4","volume":"21","author":"RM Law","year":"2020","unstructured":"Law RM, Ngo MA, Maibach HI. Twenty clinically pertinent factors\/observations for percutaneous absorption in humans. Am J Clin Dermatol. 2020;21(1):85\u201395. https:\/\/doi.org\/10.1007\/s40257-019-00480-4.","journal-title":"Am J Clin Dermatol"},{"key":"1393_CR13","unstructured":"Bristol Myers Squibb. Sotyktu. Prescribing information. 2022. https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf. Accessed 19 Nov 2024."},{"issue":"1","key":"1393_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"key":"1393_CR15","unstructured":"Lebwohl M, Kircik LH, Moore A, et al. Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: efficacy and safety from DERMIS-1 and DERMIS-2 phase 3 trials. In: The 2024 European Academy of Dermatology and Venereology Spring Symposium, 25-28 Sept, Amsterdam. https:\/\/www.arcutis.com\/wp-content\/uploads\/2021\/05\/Roflumilast-cream-Study-301-302-EADV-presentation_FINAL.pdf. Accessed 24 Jan 2025."},{"key":"1393_CR16","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.235","author":"H Sofen","year":"2023","unstructured":"Sofen H, Tyring S, Johnson SM, et al. Efficacy of tapinarof cream 1% once daily for the treatment of mild to severe intertriginous plaque psoriasis. SKIN J Cutan Med. 2023. https:\/\/doi.org\/10.25251\/skin.7.supp.235.","journal-title":"SKIN J Cutan Med."},{"issue":"4","key":"1393_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179(4):844\u201352. https:\/\/doi.org\/10.1111\/bjd.16736.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1393_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","volume":"90","author":"JF Merola","year":"2024","unstructured":"Merola JF, Parish LC, Guenther L, et al. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;90(3):485\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.020.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1393_CR19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2024.07.1521","volume":"91","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Bukhalo M, Stein Gold L, et al. A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplantar involvement. J Am Acad Dermatol. 2024;91(6):1150\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.1521.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1393_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70\u201380. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.058.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1393_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/2475530321995516","volume":"6","author":"S Muzumdar","year":"2021","unstructured":"Muzumdar S, Leonardi C, Strober B. Tofacitinib for the treatment of refractory palmoplantar psoriasis: a case series. J Psoriasis Psoriatic Arthritis. 2021;6(2):93\u20138. https:\/\/doi.org\/10.1177\/2475530321995516.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"6","key":"1393_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020;80(6):609\u201315. https:\/\/doi.org\/10.1007\/s40265-020-01291-2.","journal-title":"Drugs"},{"key":"1393_CR23","doi-asserted-by":"publisher","unstructured":"Yamamoto T. Psoriasis and connective tissue diseases. Int J Mol Sci. 2020;21(16):5803. https:\/\/doi.org\/10.3390\/ijms21165803.","DOI":"10.3390\/ijms21165803"},{"issue":"5","key":"1393_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.023.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1393_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","volume":"25","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527\u201340. https:\/\/doi.org\/10.1007\/s40257-024-00857-0.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1393_CR26","doi-asserted-by":"publisher","first-page":"adv00033","DOI":"10.2340\/00015555-3387","volume":"100","author":"M Amin","year":"2020","unstructured":"Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Derm Venereol. 2020;100(3):adv00033. https:\/\/doi.org\/10.2340\/00015555-3387.","journal-title":"Acta Derm Venereol."},{"issue":"5","key":"1393_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jaad.2012.04.039","volume":"67","author":"JJ Wu","year":"2012","unstructured":"Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of psoriasis with autoimmune diseases. J Am Acad Dermatol. 2012;67(5):924\u201330. https:\/\/doi.org\/10.1016\/j.jaad.2012.04.039.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1393_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13555-022-00695-0","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Bohannan B, Mburu S, et al. Impact of psoriatic disease on quality of life: interim results of a global survey. Dermatol Ther (Heidelb). 2022;12(4):1055\u201364. https:\/\/doi.org\/10.1007\/s13555-022-00695-0.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1393_CR29","doi-asserted-by":"publisher","first-page":"1027347","DOI":"10.3389\/fmed.2022.1027347","volume":"9","author":"PAO Felix","year":"2022","unstructured":"Felix PAO, Sampaio AL, Silva BL, Viana ALP. Early intervention in psoriasis: where do we go from here? Front Med (Lausanne). 2022;9:1027347. https:\/\/doi.org\/10.3389\/fmed.2022.1027347.","journal-title":"Front Med (Lausanne)."},{"issue":"9","key":"1393_CR30","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.jid.2022.02.013","volume":"142","author":"J Takeshita","year":"2022","unstructured":"Takeshita J, Augustin M, de Jong EMGJ, et al. Health-related QOL differs by race\/ethnicity in North American patients with psoriasis: results from PSOLAR. J Investig Dermatol. 2022;142(9):2528-31.e3. https:\/\/doi.org\/10.1016\/j.jid.2022.02.013.","journal-title":"J Investig Dermatol"},{"issue":"11","key":"1393_CR31","first-page":"16","volume":"7","author":"AF Alexis","year":"2014","unstructured":"Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16\u201324.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"1393_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.0007-0963.2004.05891.x","volume":"150","author":"W Lew","year":"2004","unstructured":"Lew W, Lee E, Krueger JG. Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. Br J Dermatol. 2004;150(4):668\u201376. https:\/\/doi.org\/10.1111\/j.0007-0963.2004.05891.x.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1393_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.36849\/jdd.2020.5347","volume":"19","author":"SR Desai","year":"2020","unstructured":"Desai SR, Alexis AF, Jacobson A. Successful management of a black male with psoriasis and dyspigmentation treated with halobetasol propionate 0.01%\/tazarotene 0.045% lotion: case report. J Drugs Dermatol. 2020;19(10):1000\u20134. https:\/\/doi.org\/10.36849\/jdd.2020.5347.","journal-title":"J Drugs Dermatol."},{"key":"1393_CR34","unstructured":"Alexis A, McMichael A, Bhutani T. et al. Visible cohort b: guselkumab demonstrates significant scalp clearance at week 16 in participants with moderate-to-severe scalp psoriasis across all skin tones. In: The 5th Annual San Diego Dermatology Symposium, 2\u20134 February 2024, San Diego. https:\/\/www.dermrefoundation.org\/uploads\/1\/2\/6\/2\/126228942\/ind_rowland.pdf. Accessed 22 Jan 2025."},{"issue":"6","key":"1393_CR35","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.jaad.2020.04.025","volume":"83","author":"A Mufti","year":"2020","unstructured":"Mufti A, Maliyar K, Walton L, Vender R, Yeung J. Guselkumab dosing interval optimization in adult patients with psoriasis: a retrospective, multicenter case series. J Am Acad Dermatol. 2020;83(6):1813\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.025.","journal-title":"J Am Acad Dermatol"},{"key":"1393_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20373","author":"A Bagit","year":"2024","unstructured":"Bagit A, Maliyar K, Mansour M, et al. Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: an international multicentre retrospective cohort study. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1393_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40257-024-00874-z","volume":"25","author":"ND Boswell","year":"2024","unstructured":"Boswell ND, Singla S, Gordon KB. Sequencing of targeted therapy in psoriasis: does it matter. Am J Clin Dermatol. 2024;25(5):795\u2013810. https:\/\/doi.org\/10.1007\/s40257-024-00874-z.","journal-title":"Am J Clin Dermatol"},{"key":"1393_CR38","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2147\/CCID.S364640","volume":"15","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Picone B, Martora F, Fabbrocini G, Megna M. Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649\u201358. https:\/\/doi.org\/10.2147\/CCID.S364640.","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"1393_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"issue":"3","key":"1393_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/bjd\/ljad473","volume":"190","author":"S Gu\u00e9nin","year":"2024","unstructured":"Gu\u00e9nin S, Andrews E, Lebwohl MG. Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis. Br J Dermatol. 2024;190(3):451\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljad473.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1393_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1056\/NEJMoa2308713","volume":"390","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Pinter A, Ferris LK, et al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390(6):510\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2308713.","journal-title":"N Engl J Med"},{"key":"1393_CR42","unstructured":"Ferris LK, Bagel J, Huang Y, et al. A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for treating moderate-to-severe plaque psoriasis: FRONTIER-2. In: The Congress of Clinical Rheumatology-West (CCR West 2024), 26-29 Sept 2024, San Diego. https:\/\/www.janssenscience.com\/media\/attestation\/congresses\/immunology\/2024\/ccr-west\/a-phase-2b-longterm-extension-doseranging-study-of-oral-jnj77242113-for-the-treatment-of-moderatetos.pdf. Accessed 22 Jan 2025."},{"issue":"10","key":"1393_CR43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","volume":"160","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(10):1066\u201374. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2701.","journal-title":"JAMA Dermatol"},{"key":"1393_CR44","unstructured":"Papp KA, Sofen H, Rubio RG, et al. Efficacy and safety of ESK-001, a highly selective oral TYK2 inhibitor, in a phase 2 study (STRIDE) and OLE study in adults with moderate-to-severe plaque psoriasis. In: The 2024 American Academy of Dermatology Annual Meeting, 27-31 March 2024, Denver. https:\/\/www.alumis.com\/file.cfm\/18\/docs\/alumis_pub_2_for_website_aad_pres_vf.pdf. Accessed 22 Jan 2025."},{"key":"1393_CR45","unstructured":"Blauvelt A, Kempers S, Hitraya E, et al. Efficacy and safety of ESK-001, a highly selective oral TYK2 inhibitor, in moderate to severe plaque psoriasis: phase 2 results through week 28. In: The 2024 European Academy of Dermatology and Venereology Congress, 25\u201328 Sept 2024, Amsterdam. https:\/\/www.alumis.com\/file.cfm\/18\/docs\/eadv_late_breaker_presentation_final.pdf. Accessed 22 Jan 2025."},{"key":"1393_CR46","unstructured":"Kwan B, Alam MM, Milligan J, et al. Characterization of ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23 for the treatment of psoriasis. In: The 2024 European Academy of Dermatology and Venereology Congress, 25\u201328 Sept 2024, Amsterdam. Abstract 4711. https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress_2024\/46185.pdf. Accessed 22 Jan 2025."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01393-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01393-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:48:38Z","timestamp":1747759718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01393-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01393-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Linda Stein Gold is an investigator, consultant, and\/or speaker for Abbvie, Arcutis, Amgen, Dermavant, Galderma, Incyte, LEO Pharma, Lilly, Pfizer, Regeneron, and Sanofi. Andrew Alexis is an investigator, consultant, and\/or speaker for AbbVie, Amgen, LEO Pharma, Galderma, Arcutis, Dermavant, Castle, Incyte, Pfizer, Sanofi-Regeneron, Genzyme, Beiersdorf, Ortho, L\u2019Oreal, Bristol Myers Squibb, Bausch Health, UCB, Janssen, Allergan, Almirall, VisualDx, Eli Lilly and Company, Swiss American, Cutera, Cara Therapeutics, EPI, Incyte, Castle, Apogee, Canfield Scientific, Alphyn Biologics, Avita Medical, Genentech, Boehringer Ingelheim, Johnson and Johnson, Aerolase, Springer, Wiley-Blackwell, Wolters Kluwer Health, and Elsevier. Brad Glick is an investigator, consultant, speaker, and\/or stakeholder for AbbVie, Amgen, Arcutis, AstraZeneca, Bellus Medical, Brickell Biotech, Bristol Myers Squibb, Cara Therapeutics, ChemoCentryx, CorEvitas Registry PSO, CorEvitas Registry AD, Dermavant, Dermira, Eli Lilly and Company, Galderma, Incyte, Janssen, LEO Pharma, Nimbus Lakshmi, Novartis, Ortho, Pfizer, PROSE Registry for AD, Regeneron, Sanofi-Genzyme, Sun Pharmaceutical Industries, Top MD, and UCB. Mona Shahriari is an investigator, consultant, and\/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Cara Therapeutics, CorEvitas Registry PSO, CorEvitas Registry AD, Dermavant, Dermira, Galderma, Incyte, Janssen, LEO Pharma, Lilly USA, Mindera Health, Novartis, Pfizer, Sanofi-Genzyme, Regeneron, UCB, and Union Therapeutics. Eingun James Song is an investigator, consultant, and\/or speaker for AbbVie, Alphyn Biologics, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, DermBiont, Galderma, Incyte, Janssen, LEO Pharma, MoonLake, Novartis, Ortho, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, Timber Pharmaceuticals, and UCB. Bruce Strober is an investigator, consultant, speaker, and\/or stockholder for AbbVie, Alumis, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, Connect Biopharma, CorEvitas Registry PSO, Dermavant, Janssen, LEO Pharma, Eli Lilly and Company, Mindera Health, Maruho, Meiji Seika Pharma, Novartis, Oruka Therapeutics, Protagonist, Pfizer, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, Takeda, UCB, Union Therapeutics. Najat M. Watch and Melodie Young report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All experts who took part in this conference are the authors of this manuscript, therefore ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}